Volume: 12 Issue: 2
Year: 2024, Page: 15-21, Doi: https://doi.org/10.47799/pimr.1202.03
Received: Feb. 20, 2024 Accepted: May 14, 2024 Published: Aug. 16, 2024
Immunohistochemistry in cancer diagnosis holds great potential to improve patient’s outcomes through enhanced diagnostic accuracy and more effective treatment strategies. Antigen-antibody interactions is one of its main objectives that utilizes the specific binding of antibodies to cellular antigens allowing for the precise identification and localization of specific proteins within tissue samples. However, there exist practical hitches in the form of tissue fixation, epitope retrieval, and antibody quality. It is crucial to continue streamlining the techniques and scoring systems to guarantee their reliability in various contexts. Understanding the interactions is pivotal for the accurate diagnosis, prognosis, and future perspectives. As technology continues to advance and our understanding of cancer biology deepens, immunohistochemistry will remain an invaluable tool for precision in cancer diagnosis.
Keywords: Principle of Immunohistochemistry, Cancer diagnosis, Diagnostic Biomarkers
Allred, D C, Harvey, J M, Berardo, M & Clark, G M . 1998. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathology 11(2):155–168.
Taylor, C R, Levenson, R M, Quantitative, R F & Immunohistochemistry, . 2010. The Relevance of Research Antibody Validation. Modern Pathology 23(3):277–287.
Harvey, J M, Clark, G M, Osborne, C K & Allred, D C . 1999. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. Journal of Clinical Oncology 17(5):1474–1481.
Ross, J S, Slodkowska, E A, Symmans, W F, Pusztai, L & Ravdin, P M . 2009. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. The Oncologist 14(4):320–368.
Mclaughlin, J, Han, G, Schalper, K A, Carvajal-Hausdorf, D, Pelekanou, V, Rehman, J, Chen & L . 2016. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncology 2(1):46–54.
Press, M F, Sauter, G, Buyse, M, Bernstein, L, Guzman, R, Santiago, A, Van De, & Vijver, M J . 2016. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. Journal of Clinical Oncology 29(7):859–867.
Coons, A H . 1941. The demonstration of pneumococcal antigen in tissues by the use of fluorescent antibodies. Journal of Immunology 42(2):159–170.
Kohler, G & Milstein, C . 1975. Continuous cultures of fused cells secreting antibodies of predefined specificity. Nature 256(5517):495–497.
Gown, A M . 2008. Current issues in ER and HER2 testing by IHC in breast cancer. Modern Pathology 21(S2):8–15.
Magaki, S, Hojat, S A, Wei, B, So, A & Wh, Yong . 2019. Methods Mol. Biol 1897:289–298.
Gown, A M & Goldblum, J R . 2002. Tissue-specific diagnostic markers: the ones that got away. Virchows Archiv 441(2):111–122.
Gutierrez, C, Neff, R T & Faso, A . 2018. Current and emerging immuno-oncology biomarkers. Seminars in Cancer Biology 52:228–241.
Taylor, C R & Levenson, R M . 2006. Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment I. Histopathology 49(4):406–410.
Vergara, D, Simeone, P & Damato, M . 2017. Standardization of immunohistochemical procedures; How far are we from the general diffusion? Analytical Cellular Pathology 6324954.
Lan, W & Xiong, Y . 2018. Immunohistochemistry in tumor grading. Immunohistochemistry 203–212.
Loeb, S & Catalona, W J . 2008. The Prostate Health Index: A New Test for the Detection of Prostate Cancer. Therapeutic Advances in Urology (5) 331–334.
Cheang, M C, Chia, S K, Voduc, D, Gao, D, Leung, S, Snider, J & Nielsen, T O . 2009. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. Journal of the National Cancer Institute (10) 736–750.
Topalian, S L, Taube, J M, Anders, R A & Pardoll, D M . 2016. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nature Reviews Cancer 16(5):275–287.
Cappuzzo, F, Ligorio, C, Janne, P A, Toschi, L, Rossi, E, Trisolini, R & Crino, L . 2005. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology 23(9):2510–2516.
Goldhirsch, A, Winer, E P, Coates, A S, Gelber, R D, Piccart-Gebhart, M, Thürlimann, B & Senn, H J . 2013. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Annals of oncology 24(9):2206–2223.
Yarden, Y & Pines, G . 2012. and The ERBB network: at last, cancer therapy meets systems biology. Nat. Rev. Cancer 12:553–563.
Hans, C P, Weisenburger, D D, Greiner, T C, Gascoyne, R D, Delabie, J, Ott, G & Fu, K . 2004. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, the Journal of the American Society of Hematology 103(1):275–282.
Slamon, D J, Clark, G M, Wong, S G, Levin, W J, Ullrich, A & Mcguire, W L . 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182.
Lindeman, N I, Cagle, P T, Beasley, M B, Chitale, D A, Dacic, S, Giaccone, G & Wistuba, I . 2013. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Archives of Pathology & Laboratory Medicine 137(6):828–860.
Owens, M A & Goel, V . 2006. Immunohistochemistry for assessment of immunophenotype in tumors: clinical applications. Archives of pathology & laboratory medicine 130(7):1006–1015.
Jørgensen, J T . 2010. Biomarkers: On the Path to Personalized Medicine? Comparative and Functional Genomics 1–9.
Duffy, M J & Crown, J . 2008. Biomarkers for Predicting Response to Treatment in Advanced Breast Cancer. The Breast Journal 14(4):327–333.
Strimbu, K & Tavel, J A . 2010. What Are Biomarkers? Current Opinion in HIV and AIDS 5(6):463–466.
Harris, L, Fritsche, H, Mennel, R, Norton, L, Ravdin, P, Taube, S & Bast, R C . 2007. Update of Recommendations for the Use of Tumor Markers in Breast Cancer. Journal of Clinical Oncology 25(33):5287–5312.
Simon, R . 2016. Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers. Annals of Oncology 27(12):1127–1133.
Santarpia, L, Lippman, S M & El-Naggar, A K . 2012. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets 16(1):103–119.
Esserman, L J, Thompson, I M & Reid, B . 2014. Overdiagnosis and Overtreatment in Cancer: An Opportunity for Improvement. JAMA (8) 797–798.
Dancey, J E, Dobbin, K K, Groshen, S & Jessup, J M . 2012. Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents. Clinical Cancer Research 18(18):5172–5181.
Mazor, K M, Beard, R L, Alexander, G L, Arora, N K, Uhlmann, R A & Street, R L . 2011. Patients’ and Family Members’ Views on Patient-Centered Communication during Cancer Care. Psycho-Oncology 20(12):1301–1308.
Elkin, E B, Marshall, D A, Kind, P, Weinstein, M C & Weycker, D . 2010. The Impact of Willingness to Pay on Cost-Effectiveness Assessments in Health Care. Health Economics 19(4):479–490.
Chu, P G & Weiss, L M . 2002. Keratin expression in human tissues and neoplasms. Histopathology 40(5):403–439.
Wolff, A C, Hammond, M E, Hicks, D G, Dowsett, M, Mcshane, L M, Allison, K H & Badve, S . 2013. of Clinical Oncology/College of American Pathologists clinical practice guideline update. Journal of Clinical Oncology 31(31):3997–4013.
Travis, W D, Brambilla, E, Noguchi, M, Nicholson, A G, Geisinger, K R, Yatabe, Y & Politi, E . 2011. International Association for the Study of Lung Cancer. Journal of Thoracic Oncology 6(2):244–285.
Varadhachary, G R . 2014. Carcinoma of unknown primary: focused evaluation. Journal of oncology practice 10(3):182–190.
©2024 (Solomon MaƩhias Gamde) . This is an open-access journal, and articles are distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are credited.
Gamde SM, Francis L, Adisa JO. Immunohistochemistry in Cancer Diagnosis: A Review. PerspecƟves in Medical Research. 2024;12(2):15-21 DOI: 10.47799/pimr.1202.03